Darbepoetin alfa: a new therapy for the management of anaemia associated with chronic kidney disease

Bibliography

• JONES C, MCQUILLAN G, KUSEK J et al.: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am. I Kidney Dis. (1998) 32:992–999.
   PubMed Web of Science ®Google Scholar
• LINDBERG J, FORET J, PITTS L et al.: Impact of rHuEPO injections on the daily routines of CRI patients. Proceedings of the 33rd National Symposium of the American Nephrology Nurses' Association Congress. Orlando, FL, USA (2002).
   Google Scholar
• CARO J, BROWN S, MILLER 0, MURRAY T, ERSLEV AJ: Erythropoietin levels in uremic, nephric and anephric patients. I Lab. Clin. Med. (1979) 93:449–458.
   PubMed Web of Science ®Google Scholar
• ESCHBACH JVV: The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney hat. (1989) 35:134–148.
   PubMed Web of Science ®Google Scholar
• ESCHBACH JW, DOWNING MR, EGRIE JC et al.: USA multicenter clinical trial with recombinant human erythropoietin. Contrib. Nephrol. (1989) 76:160–165.
   PubMedGoogle Scholar
• SUNDAL E, KAESER U: Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol. Dial. Transplant. (1989) 4:979–987.
   PubMed Web of Science ®Google Scholar
• JOY MS: Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann. Pharmacother. (2002) 36:1183–1192.
   PubMed Web of Science ®Google Scholar
• MACDOUGALL IC, GRAY SJ, ELSTON 0 et al: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. I Am. Soc. Nephrol. (1999) 10:2392–2395.
   PubMed Web of Science ®Google Scholar
• ••A core study establishing the longer half-lifeof darbepoetin alfa relative to rHuEPO.
   Google Scholar
• EGRIE JC, BROWNE JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant. (2001) 16\(Suppl. 3):3–13.
   Google Scholar
• ••Reviews the rationale for the developmentof darbepoetin alfa and its pharmacology.
   Google Scholar
• AMGEN INC.: Aranesp° (darbepoetin alfa) package insert. Thousand Oaks, CA (2001).
   Google Scholar
• NISSENSON AR: Novel erythropoesis stimulating protein for managing the anemia of chronic kidney disease. Am. I Kidney Dis. (2001) 38:1390–1397.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive overview of darbepoetinalfa preclinical and clinical trial data.
   Google Scholar
• MACDOUGALL IC: Novel erythropoiesis stimulating protein. Semin. Nephrol. (2000) 20:375–381.
   PubMed Web of Science ®Google Scholar
• EGRIE JC, DWYER E, LYKOS M, HITZ A, BROWNE JK Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood (1997) 90:56a.
   Google Scholar
• AKAHORI H, TAWARA T, IDA M, MIYAZAKI H: The effect of novel erythropoiesis stimulating protein (NESP) on anemia induced by renal failure in rats. Exp. Hematol. (1998) 26:766.
   Web of Science ®Google Scholar
• ALLON M, KLEINMAN K, WALCZYK M et al.: The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following intravenous administration is time-and dose-linear. I Am. Soc. Nephrol. (2000) 11:A1308. [Accepted as a full paper in Clinical Pharmacology and Therapeutics, August 2002. Title: Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in dialysis patients].
   Google Scholar
• GRAF H, LACOMBE J-L, BRAUN J, GOMES DA COSTA AA, AND THE EUROPEAN/AUSTRALIAN NESP 980140/194 STUDY GROUP: Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients. I Am. Soc. Nephrol.(2000) 11:A1317.
   PubMedGoogle Scholar
• LERNER GR, KALE AS, WARADY BA et al.: The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in pediatric patients with chronic renal failure (CRF) or end-stage renal disease. Am. Soc. Nephrol. (2000) 11:A1479. [Accepted as a full paper by Pediatric Nephrology September 2002. Available online: DOI 10.1007/ s00467-002-0932-0. Title: Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease].
   Google Scholar
• EVANS JH, BROCKLEBANK JT, BOWMER CJ, NG PC: Pharmacokinetics of recombinant human erythropoietin inchildren with renal failure. Nephrol. Dial. Transplant. (1991) 6:709–714.
   PubMed Web of Science ®Google Scholar
• GLASPY J, JADEJA J, JUSTICE Get at.: Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br. Cancer. (2002) 87:268–276.
   Google Scholar
• KOTASEK D, ALBERTSSON M, MACKEY J et al: Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors. Proc. ASCO (2002) 21:356a.
   Google Scholar
• GLASPY J, JADEJA J, JUSTICE G et a/.: Optimizing the management of anemia in cancer patients: a randomised, active-controlled study investigating the dosing of darbepoetin alfa. Proc. ASCO(2002) 21:367a.
   Google Scholar
• SMITH R, TCHEKMEDYIAN S, RICHARDS D et al: Darbepoetin alfa effectively alleviates anemia in patients with chronic anemia of cancer: efficacy and pharmacokinetic results of a dose-escalation study. Proc. ASCO (2002) 21:367a.
   Google Scholar
• BOCHICCHIO T, CORREA-ROTTER R, TRINIDAD RP et al: Novel erythropoiesis stimulating protein effectively maintains hemoglobin when administered at a reduced dose frequency compared with recombinant human erythropoietin in dialysis patients in Mexico. Proceedings of the American Socie0, of Nephrology/International Socie0, of Nephrology World Congress of Nephrology San Francisco, CA, USA (2001).
   Google Scholar
• MACDOUGALL IC: Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int. (2002) 61\(Suppl. 80):555–561.
   Google Scholar
• ••A comprehensive overview of darbepoetinalfa predinical and clinical trial data.
   Google Scholar
• LOCATELLI F, OLIVARES J, WALKER R: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney hat. (2001)60:741–747.
   PubMed Web of Science ®Google Scholar
• ••A core study reporting data on the efficacyand tolerability of darbepoetin alfa in patients with CKD not receiving dialysis.
   Google Scholar
• LINDBERG JS, NAVARRO J,SURANYI M, WALKER R: Aranesp' (darbepoetin alfa) administered once every other week (q2w) corrects anemia in patients with chronic kidney disease (CKD). Proceedings of the National Kidney Foundation Clinical Nephrology Meeting. Chicago, IL, USA (2002).
   Google Scholar
• NISSENSON AR, SWAN SK, LINDBERG JS et al.: Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am. I Kidney Dis. (2002) 40:110–118.
   PubMed Web of Science ®Google Scholar
• VANRENTERGHEM Y, BARANY P, MANN J: Novel erythropoiesis stimulating protein (NESP) maintains Hb in ESRD patients when administered once weekly or once every other week.' Am. Soc. Nephrol (1999) 10:270A. [Accepted as a full paper by Kidney International, August 2002. Title: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with epoetin alfa in dialysis patients].
   Google Scholar
• WALKER R Aranesp (darbepoetin alfa)administered at a reduced frequency of once every 4 weeks (q4w) maintains hemoglobin levels in patients with chronic kidney disease receiving dialysis. Proceedings of theNational Kidney Foundation Clinical Nephrology Meeting. Chicago, IL, USA (2002).
   Google Scholar
• •An abstract reporting data on the efficacy and tolerability of darbepoetin alfa with once-monthly dosing.
   Google Scholar
• RAHMAN SN, HEIFNER KJ,FADEM SZ et al: HRQOL improvements in anemic CKD patients treated with darbepoetin alfa (Aranesp'). Proceedings of the National Kidney Foundation Clinical Nephrology Meeting. Chicago, IL, USA (2002).
   Google Scholar
• •An abstract assessing the impact of early anaemia correction on HRQOL in patients with CKD.
   Google Scholar
• CASADEVALL N, NATAF J, VIRON B et al.: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl. Med. (2002) 346:469–475.
   PubMed Web of Science ®Google Scholar
• JANSSEN-ORTHO INC, ORTHO BIOTECH: Important new safety information EPREX (epoetin alfa): reports of pure red blood cell aplasia. Healthcare Professional Letter (2001) November 26.
   Google Scholar
• http://www.health.gov/healthypeople NATIONAL INSTITUTES OF HEALTH: Healthy people 2010: chronic kidney disease 2000.
   Google Scholar